RSV/hMPV mRNA Vaccine(Sanofi Pasteur)(RSV/hMPV mRNA Vaccine(Sanofi Pasteur)) - 在研适应症：人类偏肺病毒感染，呼吸道合胞体病毒感染，副流感病毒感染 NOS_专利_临床

概要

基本信息

药物类型

预防性疫苗、mRNA疫苗

别名

RSV/hMPV vaccine(Sanofi Pasteur)、Respiratory Syncytial Virus/Human Metapneumovirus Vaccine(Sanofi Pasteur)

靶点-

作用机制

免疫刺激剂

治疗领域

感染

在研适应症

人类偏肺病毒感染呼吸道合胞体病毒感染副流感病毒感染 NOS+ [1]

非在研适应症-

原研机构

Sanofi Pasteur

在研机构

Sanofi Pasteur

非在研机构-

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

4

项与 RSV/hMPV mRNA Vaccine(Sanofi Pasteur) 相关的临床试验

NCT06583031 / Not yet recruiting临床1期

A Phase 1, Randomized, Modified Double-blind, Multi-center, Parallel Group, Multi-arm Study to Investigate the Safety and Immunogenicity of an RSV/hMPV Vaccine Candidate in Adult Participants Aged 60 to 75 Years

VAV00039 is a first-in-human (FiH) study to assess the safety and immunogenicity (in adult participants aged 60-75 years) after a single injection of different dose formulations of an RSV/hMPV vaccine candidate and RSV vaccine.

开始日期2024-09-23

申办/合作机构

Sanofi Pasteur

NCT06604767 / Recruiting临床1期

A Phase 1, Dose-Escalation, Randomized, Active-Controlled, Modified Double-Blind, Parallel-Group, Multi-Arm Study to Investigate the Safety and Immunogenicity of a Combined Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adult Participants Aged 60 Years and Older

The purpose of this phase 1 study is to evaluate whether the vaccine is safe and can help the body to develop germ fighting agents called "antibodies" (immunogenicity) against the respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus type 3 (PIV3). The study will use different doses of PIV3 only and different combinations of RSV/hMPV/PIV3 or RSV/hMPV or only RSV vaccine in adults aged 60 years and older.

开始日期2024-09-17

申办/合作机构

Sanofi Pasteur

NCT06237296 / Active, not recruiting临床1期

A Phase I, Dose-escalation, Parallel-group, Randomized, Multi-center Study to Assess Safety and Immunogenicity of an RSV/hMPV mRNA Vaccine Candidate in Healthy Participants Aged 18 to 49 Years and 60 Years and Older.

The purpose of this study is to evaluate the safety and immunogenicity an investigational messenger ribonucleic acid (mRN)A vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) and/or human metapneumovirus (hMPV) in older adults. A single intramuscular (IM) injection of 3 to 4 different doses of the RSV/hMPV mRNA vaccine candidate formulated with 2 different lipid nanoparticles (LNP) will be administered to healthy participants aged 18 to 49 years and 60 years and older.
Treatment:
* RSV/hMPV mRNA / LNP 1 at 3-4 different doses or,
* RSV/hMPV mRNA / LNP 2 at 3-4 difference doses or,
* RSV mRNA / LNP 1 at 1 dose or,
* hMPV mRNA / LNP 1 at 1 dose

开始日期2024-01-23

申办/合作机构

Sanofi Pasteur

100 项与 RSV/hMPV mRNA Vaccine(Sanofi Pasteur) 相关的临床结果

登录后查看更多信息

100 项与 RSV/hMPV mRNA Vaccine(Sanofi Pasteur) 相关的转化医学

登录后查看更多信息

100 项与 RSV/hMPV mRNA Vaccine(Sanofi Pasteur) 相关的专利（医药）

登录后查看更多信息

9

项与 RSV/hMPV mRNA Vaccine(Sanofi Pasteur) 相关的文献（医药）

2022-09-01·Immunity

Potently neutralizing and protective anti-human metapneumovirus antibodies target diverse sites on the fusion glycoprotein

Article

作者: McLellan, Jason S ; Rush, Scott A ; Walker, Laura M ; Wec, Anna Z ; Delgado, Teresa ; Rappazzo, C Garrett ; Sakharkar, Mrunal ; Geoghegan, James C ; Más, Vicente ; Hsieh, Ching-Lin ; Esterman, Emma S

Human metapneumovirus (hMPV) is a leading cause of acute lower respiratory tract infections in high-risk populations, yet there are no vaccines or anti-viral therapies approved for the prevention or treatment of hMPV-associated disease. Here, we used a high-throughput single-cell technology to interrogate memory B cell responses to the hMPV fusion (F) glycoprotein in young adult and elderly donors. Across all donors, the neutralizing antibody response was primarily directed to epitopes expressed on both pre- and post-fusion F conformations. However, we identified rare, highly potent broadly neutralizing antibodies that recognize pre-fusion-specific epitopes and structurally characterized an antibody that targets a site of vulnerability at the pre-fusion F trimer apex. Additionally, monotherapy with neutralizing antibodies targeting three distinct antigenic sites provided robust protection against lower respiratory tract infection in a small animal model. This study provides promising monoclonal antibody candidates for passive immunoprophylaxis and informs the rational design of hMPV vaccine immunogens.

2020-12-01·Journal of Medical Virology4区 · 医学

The role of M2‐2 PDZ‐binding motifs in pulmonary innate immune responses to human metapneumovirus

4区 · 医学

Article

作者: Bao, Xiaoyong ; Chen, Yu ; Choi, Eun‐Jin ; Yan, Weiyu ; Wu, Wenzhe ; Choudhury, Atanu ; Li, Liqing

AbstractHuman metapneumovirus (HMPV) is a leading cause of lower respiratory tract infection (LRTI) in pediatric and geriatric populations. We recently found that two PDZ‐binding motifs of the M2‐2 protein, 29‐DEMI‐32 and 39‐KEALSDGI‐46, play a significant role in mediating HMPV immune evasion in airway epithelial cells (AECs). However, their role in the overall pulmonary responses to HMPV infection has not been investigated. In this study, we found that two recombinant HMPVs (rHMPV) lacking the individual M2‐2 PDZ‐binding motif are attenuated in mouse lungs. Mice infected with mutants produce more cytokines/chemokines in bronchoalveolar lavage (BAL) fluid compared to mice infected with wild‐type rHMPV. In addition, both mutants are able to enhance the pulmonary recruitment of dendritic cells (DCs) and T cells and induce effective protections against the HMPV challenge. The DC maturation is also significantly improved by the motif mutation. Taken together, our data provide proof‐of‐principle for two live‐attenuated M2‐2 mutants to be promising HMPV vaccine candidates that are effective in inducing higher pulmonary innate immunity and generating protection against HMPV infection.

2019-10-01·Journal of Virology2区 · 医学

A Potent Neutralizing Site III-Specific Human Antibody Neutralizes Human Metapneumovirus In Vivo

2区 · 医学

Article

作者: Murray, Jackelyn ; Huang, Jiachen ; Diaz, Darren ; Pena-Briseno, Alma ; Mousa, Jarrod J. ; Bar-Peled, Yael ; Tripp, Ralph A.

Recent progress in understanding the human immune response to respiratory syncytial virus has paved the way for new vaccine antigens and therapeutics to prevent and treat disease. Progress toward understanding the immune response to human metapneumovirus (hMPV) has lagged behind, although hMPV is a leading cause of lower respiratory tract infection in children. In this report, we advanced the field by isolating a panel of human mAbs to the hMPV F protein. One potent neutralizing mAb, MPV364, targets antigenic site III on the hMPV F protein and incorporates two protomers into its epitope yet is unique from previously discovered site III mAbs, as it does not cross-react with the RSV F protein. We further examined MPV364 in vivo and found that it limits viral replication in BALB/c mice. Altogether, these data provide new mAb candidates for therapeutic development and provide insights into hMPV vaccine development.

100 项与 RSV/hMPV mRNA Vaccine(Sanofi Pasteur) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
人类偏肺病毒感染	临床2期	美国	Sanofi Pasteur	2023-11-01
人类偏肺病毒感染	临床2期	波多黎各	Sanofi Pasteur	2023-11-01
呼吸道合胞体病毒感染	临床2期	波多黎各	Sanofi Pasteur	2023-11-01
呼吸道合胞体病毒感染	临床2期	美国	Sanofi Pasteur	2023-11-01
副流感病毒感染 NOS	临床1期	澳大利亚	Sanofi Pasteur	2024-09-17
人偏肺病毒感染	临床1期	澳大利亚	Sanofi Pasteur	2024-01-23
人偏肺病毒感染	临床1期	美国	Sanofi Pasteur	2024-01-23